Therefore, it is advantageous to diverge from the previously recognized targets and investigate novel targets within the peripheral branches in order to further our understanding of the biological consequences of PI3K/AKT/mTOR signaling, and benefit from this anti-tumor therapeutic strategy. This evidence concerns the gene AKT1 and neoplasm.